Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes

SMART program 2001 data

Po Ren Hsueh, Lee Jene Teng, Chun Ming Lee, Wen Kuei Huang, Tsu Lan Wu, Jen Hsien Wan, Dine Yang, Jainn Ming Shyr, Yin Ching Chuang, Jing Jou Yan, Jang Jih Lu, Jiunn Jong Wu, Wen Chien Ko, Feng Yee Chang, Yi Chueh Yang, Yeu Jun Lau, Yung Ching Liu, Hsieh Shong Leu, Cheng Yi Liu, Kwen Tay Luh

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

This study evaluated the current status of antimicrobial resistance in clinical isolates of Streptococcus pyogenes in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. In 2001, 419 different isolates of S. pyogenes, including 275 from respiratory secretions, 87 from wound pus, and 31 from blood, were collected from nine hospitals in different parts of Taiwan. MICs of 23 antimicrobial agents were determined at a central location by the agar dilution method. All of the isolates were susceptible to penicillin (MIC at which 90% of the isolates were inhibited [MIC90], ≤0.03 μg/ml), cefotaxime (MIC90, ≤0.03 μg/ml), cefepime (MIC90, 0.06 μg/ml), meropenem (MIC90, ≤0.03 μg/ml), moxifloxacin (MIC90, 0.25 μg/ml), vancomycin (MIC90, 0.5 μg/ml), and linezolid (MIC90, 1 μg/ml). Overall, 78% of isolates were not susceptible to erythromycin (54% were intermediate, and 24% were resistant), and 5% were not susceptible to clindamycin. Of the 101 erythromycin-resistant isolates, 80.2% exhibited the M phenotype (mefA gene positive), 18.9% exhibited the cMLS (constitutive resistance to macrolides-lincosamides-streptogramin B [MLS]) phenotype (ermB gene positive), and 1% exhibited the iMLS (inducible resistance to MLS) phenotype (ermB gene positive). Fluoroquinolones (sitafloxacin > moxifloxacin > ciprofloxacin = levofloxacin = gatifloxacin > gemifloxacin) demonstrated potent activity against nearly all of the isolates of S. pyogenes tested. Thirty-two isolates (8%) were not susceptible to quinupristin-dalfopristin. Seventeen percent of isolates had telithromycin MICs of ≥1 μg/ml, and all of these isolates exhibited erythromycin MICs of ≥32 μg/ml. The high prevalence of resistance to telithromycin (which is not available in Taiwan) limits its potential use in the treatment of S. pyogenes infections, particularly in areas with high rates of macrolide resistance.

Original languageEnglish
Pages (from-to)2152-2157
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume47
Issue number7
DOIs
Publication statusPublished - Jul 1 2003
Externally publishedYes

Fingerprint

Streptococcus pyogenes
Taiwan
Macrolides
Erythromycin
Streptogramin B
Lincosamides
Linezolid
meropenem
Phenotype
Genes
Levofloxacin
Cefotaxime
Suppuration
Clindamycin
Fluoroquinolones
Vancomycin
Ciprofloxacin
Anti-Infective Agents
Penicillins
Agar

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes : SMART program 2001 data. / Hsueh, Po Ren; Teng, Lee Jene; Lee, Chun Ming; Huang, Wen Kuei; Wu, Tsu Lan; Wan, Jen Hsien; Yang, Dine; Shyr, Jainn Ming; Chuang, Yin Ching; Yan, Jing Jou; Lu, Jang Jih; Wu, Jiunn Jong; Ko, Wen Chien; Chang, Feng Yee; Yang, Yi Chueh; Lau, Yeu Jun; Liu, Yung Ching; Leu, Hsieh Shong; Liu, Cheng Yi; Luh, Kwen Tay.

In: Antimicrobial Agents and Chemotherapy, Vol. 47, No. 7, 01.07.2003, p. 2152-2157.

Research output: Contribution to journalArticle

Hsueh, PR, Teng, LJ, Lee, CM, Huang, WK, Wu, TL, Wan, JH, Yang, D, Shyr, JM, Chuang, YC, Yan, JJ, Lu, JJ, Wu, JJ, Ko, WC, Chang, FY, Yang, YC, Lau, YJ, Liu, YC, Leu, HS, Liu, CY & Luh, KT 2003, 'Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART program 2001 data', Antimicrobial Agents and Chemotherapy, vol. 47, no. 7, pp. 2152-2157. https://doi.org/10.1128/AAC.47.7.2152-2157.2003
Hsueh, Po Ren ; Teng, Lee Jene ; Lee, Chun Ming ; Huang, Wen Kuei ; Wu, Tsu Lan ; Wan, Jen Hsien ; Yang, Dine ; Shyr, Jainn Ming ; Chuang, Yin Ching ; Yan, Jing Jou ; Lu, Jang Jih ; Wu, Jiunn Jong ; Ko, Wen Chien ; Chang, Feng Yee ; Yang, Yi Chueh ; Lau, Yeu Jun ; Liu, Yung Ching ; Leu, Hsieh Shong ; Liu, Cheng Yi ; Luh, Kwen Tay. / Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes : SMART program 2001 data. In: Antimicrobial Agents and Chemotherapy. 2003 ; Vol. 47, No. 7. pp. 2152-2157.
@article{b7f30676cfcd4ea7aa1de953a120d807,
title = "Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART program 2001 data",
abstract = "This study evaluated the current status of antimicrobial resistance in clinical isolates of Streptococcus pyogenes in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. In 2001, 419 different isolates of S. pyogenes, including 275 from respiratory secretions, 87 from wound pus, and 31 from blood, were collected from nine hospitals in different parts of Taiwan. MICs of 23 antimicrobial agents were determined at a central location by the agar dilution method. All of the isolates were susceptible to penicillin (MIC at which 90{\%} of the isolates were inhibited [MIC90], ≤0.03 μg/ml), cefotaxime (MIC90, ≤0.03 μg/ml), cefepime (MIC90, 0.06 μg/ml), meropenem (MIC90, ≤0.03 μg/ml), moxifloxacin (MIC90, 0.25 μg/ml), vancomycin (MIC90, 0.5 μg/ml), and linezolid (MIC90, 1 μg/ml). Overall, 78{\%} of isolates were not susceptible to erythromycin (54{\%} were intermediate, and 24{\%} were resistant), and 5{\%} were not susceptible to clindamycin. Of the 101 erythromycin-resistant isolates, 80.2{\%} exhibited the M phenotype (mefA gene positive), 18.9{\%} exhibited the cMLS (constitutive resistance to macrolides-lincosamides-streptogramin B [MLS]) phenotype (ermB gene positive), and 1{\%} exhibited the iMLS (inducible resistance to MLS) phenotype (ermB gene positive). Fluoroquinolones (sitafloxacin > moxifloxacin > ciprofloxacin = levofloxacin = gatifloxacin > gemifloxacin) demonstrated potent activity against nearly all of the isolates of S. pyogenes tested. Thirty-two isolates (8{\%}) were not susceptible to quinupristin-dalfopristin. Seventeen percent of isolates had telithromycin MICs of ≥1 μg/ml, and all of these isolates exhibited erythromycin MICs of ≥32 μg/ml. The high prevalence of resistance to telithromycin (which is not available in Taiwan) limits its potential use in the treatment of S. pyogenes infections, particularly in areas with high rates of macrolide resistance.",
author = "Hsueh, {Po Ren} and Teng, {Lee Jene} and Lee, {Chun Ming} and Huang, {Wen Kuei} and Wu, {Tsu Lan} and Wan, {Jen Hsien} and Dine Yang and Shyr, {Jainn Ming} and Chuang, {Yin Ching} and Yan, {Jing Jou} and Lu, {Jang Jih} and Wu, {Jiunn Jong} and Ko, {Wen Chien} and Chang, {Feng Yee} and Yang, {Yi Chueh} and Lau, {Yeu Jun} and Liu, {Yung Ching} and Leu, {Hsieh Shong} and Liu, {Cheng Yi} and Luh, {Kwen Tay}",
year = "2003",
month = "7",
day = "1",
doi = "10.1128/AAC.47.7.2152-2157.2003",
language = "English",
volume = "47",
pages = "2152--2157",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes

T2 - SMART program 2001 data

AU - Hsueh, Po Ren

AU - Teng, Lee Jene

AU - Lee, Chun Ming

AU - Huang, Wen Kuei

AU - Wu, Tsu Lan

AU - Wan, Jen Hsien

AU - Yang, Dine

AU - Shyr, Jainn Ming

AU - Chuang, Yin Ching

AU - Yan, Jing Jou

AU - Lu, Jang Jih

AU - Wu, Jiunn Jong

AU - Ko, Wen Chien

AU - Chang, Feng Yee

AU - Yang, Yi Chueh

AU - Lau, Yeu Jun

AU - Liu, Yung Ching

AU - Leu, Hsieh Shong

AU - Liu, Cheng Yi

AU - Luh, Kwen Tay

PY - 2003/7/1

Y1 - 2003/7/1

N2 - This study evaluated the current status of antimicrobial resistance in clinical isolates of Streptococcus pyogenes in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. In 2001, 419 different isolates of S. pyogenes, including 275 from respiratory secretions, 87 from wound pus, and 31 from blood, were collected from nine hospitals in different parts of Taiwan. MICs of 23 antimicrobial agents were determined at a central location by the agar dilution method. All of the isolates were susceptible to penicillin (MIC at which 90% of the isolates were inhibited [MIC90], ≤0.03 μg/ml), cefotaxime (MIC90, ≤0.03 μg/ml), cefepime (MIC90, 0.06 μg/ml), meropenem (MIC90, ≤0.03 μg/ml), moxifloxacin (MIC90, 0.25 μg/ml), vancomycin (MIC90, 0.5 μg/ml), and linezolid (MIC90, 1 μg/ml). Overall, 78% of isolates were not susceptible to erythromycin (54% were intermediate, and 24% were resistant), and 5% were not susceptible to clindamycin. Of the 101 erythromycin-resistant isolates, 80.2% exhibited the M phenotype (mefA gene positive), 18.9% exhibited the cMLS (constitutive resistance to macrolides-lincosamides-streptogramin B [MLS]) phenotype (ermB gene positive), and 1% exhibited the iMLS (inducible resistance to MLS) phenotype (ermB gene positive). Fluoroquinolones (sitafloxacin > moxifloxacin > ciprofloxacin = levofloxacin = gatifloxacin > gemifloxacin) demonstrated potent activity against nearly all of the isolates of S. pyogenes tested. Thirty-two isolates (8%) were not susceptible to quinupristin-dalfopristin. Seventeen percent of isolates had telithromycin MICs of ≥1 μg/ml, and all of these isolates exhibited erythromycin MICs of ≥32 μg/ml. The high prevalence of resistance to telithromycin (which is not available in Taiwan) limits its potential use in the treatment of S. pyogenes infections, particularly in areas with high rates of macrolide resistance.

AB - This study evaluated the current status of antimicrobial resistance in clinical isolates of Streptococcus pyogenes in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. In 2001, 419 different isolates of S. pyogenes, including 275 from respiratory secretions, 87 from wound pus, and 31 from blood, were collected from nine hospitals in different parts of Taiwan. MICs of 23 antimicrobial agents were determined at a central location by the agar dilution method. All of the isolates were susceptible to penicillin (MIC at which 90% of the isolates were inhibited [MIC90], ≤0.03 μg/ml), cefotaxime (MIC90, ≤0.03 μg/ml), cefepime (MIC90, 0.06 μg/ml), meropenem (MIC90, ≤0.03 μg/ml), moxifloxacin (MIC90, 0.25 μg/ml), vancomycin (MIC90, 0.5 μg/ml), and linezolid (MIC90, 1 μg/ml). Overall, 78% of isolates were not susceptible to erythromycin (54% were intermediate, and 24% were resistant), and 5% were not susceptible to clindamycin. Of the 101 erythromycin-resistant isolates, 80.2% exhibited the M phenotype (mefA gene positive), 18.9% exhibited the cMLS (constitutive resistance to macrolides-lincosamides-streptogramin B [MLS]) phenotype (ermB gene positive), and 1% exhibited the iMLS (inducible resistance to MLS) phenotype (ermB gene positive). Fluoroquinolones (sitafloxacin > moxifloxacin > ciprofloxacin = levofloxacin = gatifloxacin > gemifloxacin) demonstrated potent activity against nearly all of the isolates of S. pyogenes tested. Thirty-two isolates (8%) were not susceptible to quinupristin-dalfopristin. Seventeen percent of isolates had telithromycin MICs of ≥1 μg/ml, and all of these isolates exhibited erythromycin MICs of ≥32 μg/ml. The high prevalence of resistance to telithromycin (which is not available in Taiwan) limits its potential use in the treatment of S. pyogenes infections, particularly in areas with high rates of macrolide resistance.

UR - http://www.scopus.com/inward/record.url?scp=0038338387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038338387&partnerID=8YFLogxK

U2 - 10.1128/AAC.47.7.2152-2157.2003

DO - 10.1128/AAC.47.7.2152-2157.2003

M3 - Article

VL - 47

SP - 2152

EP - 2157

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -